HC Wainwright Issues Pessimistic Estimate for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings estimates for shares of Eton Pharmaceuticals in a research report issued on Tuesday, November 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $0.05 per share for the quarter, down from their previous forecast of $0.09. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.37 EPS, FY2026 earnings at $0.81 EPS and FY2027 earnings at $1.25 EPS.

Separately, Craig Hallum increased their target price on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Trading Up 2.3 %

Eton Pharmaceuticals stock opened at $12.74 on Wednesday. The firm has a 50 day moving average of $8.23 and a 200 day moving average of $5.36. The firm has a market capitalization of $329.15 million, a price-to-earnings ratio of -56.05 and a beta of 1.25. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $12.77.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eton Pharmaceuticals in the third quarter valued at $54,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals during the third quarter worth $90,000. Renaissance Technologies LLC lifted its position in shares of Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals during the second quarter worth $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the last quarter. 27.86% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, major shareholder Opaleye Management Inc. acquired 11,248 shares of the business’s stock in a transaction on Monday, October 7th. The stock was acquired at an average cost of $7.22 per share, with a total value of $81,210.56. Following the acquisition, the insider now directly owns 2,730,000 shares in the company, valued at $19,710,600. This represents a 0.41 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders acquired 85,600 shares of company stock worth $462,674 in the last three months. 14.89% of the stock is owned by company insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.